Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
=== Nonsteroidal anti-inflammatory drugs === Although individual analgesics rarely induce liver damage due to their widespread use, NSAIDs have emerged as a major group of drugs exhibiting hepatotoxicity. Both dose-dependent and idiosyncratic reactions have been documented. Aspirin and phenylbutazone are associated with intrinsic hepatotoxicity; idiosyncratic reaction has been associated with ibuprofen, sulindac, phenylbutazone, piroxicam, diclofenac and indomethacin.
== Overview == The process of translation starts with the information stored in the nucleotide sequence of DNA. This is first transformed into mRNA, then tRNA specifies which three-nucleotide codon from the genetic code corresponds to which amino acid. Each mRNA codon is recognized by a particular type of tRNA, which docks to it along a three-nucleotide anticodon, and together they form three complementary base pairs. On the other end of the tRNA is a covalent attachment to the amino acid corresponding to the anticodon sequence, with each type of tRNA attaching to a specific amino acid. Because the genetic code contains multiple codons that specify the same amino acid, there are several tRNA molecules bearing different anticodons which carry the same amino acid. The covalent attachment to the tRNA 3' end is catalysed by enzymes called aminoacyl tRNA synthetases. During protein synthesis, tRNAs with attached amino acids are delivered to the ribosome by proteins called elongation factors, which aid in association of the tRNA with the ribosome, synthesis of the new polypeptide, and translocation (movement) of the ribosome along the mRNA. If the tRNA's anticodon matches the mRNA, another tRNA already bound to the ribosome transfers the growing polypeptide chain from its 3' end to the amino acid attached to the 3' end of the newly delivered tRNA, a reaction catalyzed by the ribosome. A large number of the individual nucleotides in a tRNA molecule may be chemically modified, often by methylation or deamidation.
== External links == Kristin Tillotson, "Minnesota Opera co-commissions Cold Mountain, Minneapolis Star Tribune (Artcetera blog), 6 May 2014 Heidi Waleson, "Creating Cold Mountain: Student Singers Help to Shape a Major Modern Opera", Overtones (Curtis Institute of Music), Spring 2014 Cold Mountain, Opera Philadelphia page "Cold Mountain makes East Coast Premiere February 5–14, 2016, at the Academy of Music." Opera Philadelphia press release, 5 January 2016 Tom Huizenga, "Great Expectations: A New Season Of New Music". National Public Radio (Deceptive Cadence blog), 3 September 2014 "Jennifer Higdon writes an opera", The Musicalist podcast, 12 February 2014 Jim Cotter, "Jennifer Higdon on Cold Mountain". WRTI, 90.1 FM, 16 November 2012 Mark Gresham, "Jennifer Higdon completes her new opera, Cold Mountain". EarRelevant blog, 17 September 2013 Pentatone Records page on Cold Mountain Peter Dobrin, "Cold Mountain scores", The Philadelphia Inquirer, Blogs the Arts, 16 May 2016
== Social == Social Progress Index 2017: Thailand ranked 62 of 128 nations (1=best; 128=worst). Other ASEAN nations ranked were: Malaysia, 50; Philippines, 68; Indonesia, 79; Myanmar, 96; Cambodia, 98; and Laos, 99. Social Progress Index 2015: Social progress is the capacity of a society to meet the basic human needs of its citizens. Thailand ranked 57 of 113 nations (1=best; 133=worst). Other ASEAN states were ranked: Philippines, 64; Indonesia, 86; Cambodia, 99; Laos, 102; and Myanmar, 119. Social Progress Index 2014: Thailand ranked 59 of 132 countries State of the World's Mothers 2014: Ranked 72 of 178 countries.
Congenital deformity – The correction of vascular malformations and cleft lip and palate abnormalities. In vascular malformations, the progression of the disease distorts the skin and the underlying structure of the nose. Cleft lip and cleft palate defects usually distort the size, position, and orientation of the nasal-tip cartilages. Reconstruction of vascular malformations can involve laser treatment of the skin, and surgical excision of the deformed tissues. When the underlying cartilage support structure is disturbed, cartilage grafts and suturing of the native nasal cartilages can help improve nasal aesthetics by re-orienting the nasal tip cartilages; and cartilage-graft refinements to the nose tip are performed as required. Obstructed airways – The restoration of normal breathing by correcting nasal obstruction caused by a cosmetic rhinoplasty wherein nasal cartilages were over-aggressively trimmed, and the nose appears pinched, which compromises nasal potency (airflow), especially when the patient attempts deep inspiration. These grafting techniques restore normal breathing by increasing the size of the nose tip with baton grafts (internal cartilage), and spreader grafts to widen the nasal middle vault. Furthermore, to improve breathing a septoplasty can be performed concurrent to the reconstructive surgery; likewise, if there is turbinate hypertrophy, an inferior turbinectomy can be performed.
Sources: en.wikipedia.org
In October 2013, A&W opened its first new concept restaurant, A&W Burgers Chicken Floats. The new concept focuses on fresh made-to-order food and heavily emphasizes customer service. The menu features burgers made with fresh beef and a choice of toppings, hand-breaded chicken tenders, all-beef hot dogs, and several sides. The new management gave A&W a significant boost in the number of locations, with 2017 scheduled to have more openings than closures. For 2018, A&W projected an increase in its franchising operations and opening new restaurants. In April 2019, A&W returned to Singapore after a 16-year absence, its first location being at Jewel Changi Airport. In June 2019, the A&W chain started moving its headquarters to the University of Kentucky Coldstream Research Campus in 2019. A&W announced in March 2022 that it was going to withdraw from the Thai market due to economic losses. The restaurants shut down on March 20. A franchise was given to western New York in early 2023, with three locations, the first of which in Niagara Falls, set to open between May and June of that year. There are nearly 1,000 A&W Restaurants worldwide that are owned or franchised through A Great American Brand, with approximately 475 of these restaurants located in the U.S. as of October 2024. A&W rebounded its profits in the first half of 2024, emphasis on its growth is given mainly to single-brand restaurants, as well as restaurants in less conventional locations. In November 2024, the chain announced its entrance to the Milwaukee and Madison markets in Wisconsin.
Between the 1960s and the 2010s, the percentage of children living with their married parents in their first marriage declined from approximately three quarters to just under half. At the same time, the share of children raised by single parents rose sharply. During the 2000s and 2010s, the number of American children raised by their grandparents or other family members rather than their parents also grew. American parents of the early twenty-first century usually do not insist that their children share the same political or religious beliefs, to follow the same traditions, or to get married and have children. Rather, they emphasize ethical behavior, tolerance, generosity, and financial independence. Parents from wealthier backgrounds are less likely to have children out of wedlock and more likely to stay married, with desirable outcomes for their children, including better social and cognitive development and educational attainment. By contrast, children born into the middle class or the lower class are less likely to have married parents than before. They also tend to have younger parents who did not intend to have them and more siblings. Upper middle-class and wealthy American couples living in the cities tend to have fewer children and to invest heavily in their children in the form of breastfeeding for at least a year, giving them premium healthcare plans, sending them to private schools, and letting them eat organic foods.
Genetic associations include mutations in pulmonary surfactant proteins A1, A2, C (SFTPA1, SFTPA2B) and mucin (MUC5B). A remarkable aspect of the MUC5B variant is its high frequency of detection, as it is found in approximately 20% of individuals with Northern and Western European ancestry and in 19% of the Framingham Heart Study population. Mutations in human telomerase genes are also associated with familial pulmonary fibrosis and in some patients with sporadic IPF (e.g. the TERT, TERC genes). Recently an X-linked mutation in a third telomerase-associated gene, dyskerin (DKC1), has been described in a family with IPF.
=== Gauge === The gauge of the chain is the thickness of the drive links, and is dictated by the gauge of the bar on which it is to be run. Usual gauges are 0.043, 0.050, 0.058, 0.063 and 0.080 inches (1.1, 1.3, 1.5, 1.6 and 2.0 mm). Chain and bar gauge must match; a chain that is too large will not fit, one that is too small will fall sideways and cut poorly.
== History == IDLO was founded in 2016 to create tasty, healthy, and convenient meals for mountain hiking and expeditions. IDLO was the first company in Ukraine to package freeze-dried meals in doypacks, allowing users to prepare and consume meals directly from the pouch without the need for dishes. Its range of main courses is produced using freeze-drying technology at its facility, in accordance with food safety management systems compliant with ISO 22000/HACCP standards. Since 2020, the company has been supplying freeze-dried meals to the Ukrainian Antarctic research station Academician Vernadsky. The company's product line includes over 40 items, such as breakfasts, lunches, dinners, snacks, and beverages. Products are available in retail chains including Gorgany, Decathlon, and Intersport/Epicentr.
Sources: en.wikipedia.org
1945 In the US, the Gerontological Society of America is formed. The founder is Edmund Vincent Cowdry. 1950 Largely thanks to the collaborative efforts of Korenchevsky and Cowdry, the International Association of Gerontology is formed, later renamed to the International Association of Gerontology and Geriatrics (IAGG). The organization was registered in Belgium, and that is where its first conference took place. Slowly, gradually, the ideas began to spread that the problems of aging cannot be solved within the framework and efforts of one nation – therefore the international interaction is necessary. 1952 Peter Medawar proposed the mutation accumulation theory to explain how the aging process could have evolved. 1954 Vladimir Dilman formulated the hypothesis of aging that at first become known only in the USSR, as the elevation hypothesis. In 1968 it took the form and became known as the neuroendocrine theory of aging. 1956 Denham Harman proposed the free-radical theory of aging and demonstrated that free radical reactions contribute to the degradation of biological systems. The theory is based on the ideas of Rebeca Gerschman and her colleagues put forward in 1945. 1957 George Williams proposed the antagonistic pleiotropy hypothesis for the explanation of the emergence of aging. 1958 Physicist Gioacchino Failla proposed the hypothesis that aging is caused by the accumulation of DNA damage. The next year the hypothesis was developed by the physicist Leo Szilard, resulting in a number of related theories under the general name DNA damage theory of aging.
== Properties == An Affibody molecule consists of three alpha helices with 58 amino acids and has a molar mass of about 6 kDa. A monoclonal antibody, for comparison, is 150 kDa, and a single-domain antibody, the smallest type of antigen-binding antibody fragment, 12–15 kDa. Affibody molecules have been shown to withstand high temperatures (90 °C (194 °F)) or acidic and alkaline conditions (pH 2.5 or pH 11, respectively). Affibody molecules have ashort plasma half-life because of their small size.While this is advantageous for imaging,as the unbound tracer is rapidly cleared from the bloodstream, a longer plasma half-life is generally preferred for therapeutic applications. One approach to extend the plasma half-life of small molecules, such as affibody molecules,is to link them to an albumin-binding domain (ABD). A highly effective ABD is the 46-amino acid G148-GA3 domain, which is derived from streptococcal protein G, along with its engineered variant ABD035. This version has a strong femtomolar affinity for human serum albumin (HSA) [28]. The ABD can help prolong the serum half-life by forming a complex with serum albumin (SA) in the bloodstream, increasing the size of the complex and preventing it from being filtered by the kidneys. Binders with an affinity of down to sub-nanomolar have been obtained from native library selections, and binders with picomolar affinity have been obtained following affinity maturation. Affibody molecules conjugated to weak electrophiles bind their targets covalently.
Machine vision systems often require bright and homogeneous illumination, so features of interest are easier to process. LEDs are often used. Barcode scanners are the most common example of machine vision applications, and many of those scanners use red LEDs instead of lasers. Optical computer mice use LEDs as a light source for the miniature camera within the mouse. LEDs are useful for machine vision because they provide a compact, reliable source of light. LED lamps can be turned on and off to suit the needs of the vision system, and the shape of the beam produced can be tailored to match the system's requirements.
For services to School Governance and to Children and Young People with Special Educational Needs. Nigel Gavin Begg. Founder, Aspire Technology Solutions. For services to Digital and Technology Industry Growth in North East England. Lynda Janet Suzanne Bennett. For services to Hockey in Wales. Trudy Helen Berlet. Lately Lead Midwife for Bereavement Care, Worcestershire Acute Hospitals NHS Trust. For services to Midwifery. Professor Miriam Bernard. Professor Emerita, Social Gerontology, Keele University. For services to Ageing Research and to Older People. Jane Alison Betsworth. Headteacher, Millfields Community School, London Borough of Hackney. For services to Education. Dr. Sanjay Bhandari. Chair, Kick It Out. For services to Sport. Dr. Manav Bhavsar. Lately Clinical Lead, Critical Care. For services to Healthcare, particularly during Covid-19. Helen Binns. Manager, Families First Team, Leeds City Council. For services to Vulnerable People. Amanda Jayne Bird. Senior Supply Chain Coordinator, Leidos Europe Limited. For services to Defence Logistics. Zachary Birks. Team Leader, Ministry of Defence. For services to Defence. Professor Anthony John Bjourson. Emeritus Professor of Genomics and lately Director, Northern Ireland Centre for Stratified Medicine, Ulster University. For services to Higher Education and to Research. Anthony Grant Bloom. Chairman, Brighton and Hove Albion Football Club. For services to Association Football and to the community in Brighton. Anthony John Bloxham.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.